Appointment

9 October 2026 BSE Limited National Stock Exchange of India Limited 25th Floor, P. J. Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai - 400001 Bandra (E), Mumbai – 400051 Scrip Code: 543064 Scrip Symbol: COHANCE Dear Sir/Madam, Sub: Disclosure regarding appointment of Chief Financial Officer Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015 (“SEBI Listing Regulations”), we hereby inform that based on the recommendation of its Nomination and Remuneration Committee, the Board of Directors of the Company, at its meeting held today i.e., Friday, 9 October 2026, inter alia, has approved the following: 1. Appointment of Mr. Abhimanyu Ojha as Chief Financial Officer and Key Managerial Personnel of the Company w.e.f. 12 October 2026. The details required to be disclosed under the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30 January 2026 on the appointment is annexed. 2. Change in the authorized Key Managerial Personnel for the purpose of determining materiality of an event or information and making disclosures thereof to the Stock Exchange(s) under Regulation 30(5) of the SEBI Listing Regulations. The “Policy for Determining Material Event or Information” in pursuance to Regulation 30 of the SEBI Listing Regulations, is also amended to reflect the change effective from 12 October 2026. Name & 1. Mr. Umang Vohra, Chairman & Group CEO Designation 2. Mr. Abhimanyu Ojha, Chief Financial Officer 3. Mr. Sisir K Mishra, Company Secretary & Compliance Officer Contact Registered office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala MIDC, Mumbai, Maharashtra, 400093 Corporate office: 202, A Wing, Galaxy Towers, Plot No 1, Hyderabad Knowledge City, TSIIC Raidurg, Hyderabad, Telangana, India, 500081 Email Id: investorservices@cohance.com Contact No.: +91-40-2354 9414 The Board Meeting commenced at 7.45 pm (IST) and concluded at 8.00 pm (IST). We request you to take the above on record. Thanking you Yours faithfully, For Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited) Sisir K. Mishra Company Secretary & Compliance Officer Encl: as above Annexure Detail pursuant to Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30 January 2026 1 Name of Person Mr. Abhimanyu Ojha 2 Reason for change viz. appointment, re- Appointment of Mr. Abhimanyu Ojha as Chief Financial appointment, resignation, removal, death Officer and Key Managerial Personnel of the Company. or otherwise 3 Date of appointment / re-appointment / 12 October 2026 cessation (as applicable) and term of appointment / re-appointment Term: Not Applicable 4 Brief profile (in case of appointment) Mr. Abhimanyu Ojha has over two decades of experience leading finance functions across multinational healthcare and pharmaceutical companies. Prior to joining Cohance, he served as Global CFO & President Finance at Intas Pharmaceuticals, where he led global finance teams spanning business operations, manufacturing, R&D, accounting, treasury, audit, taxation, corporate finance, and FP&A. Earlier, he held several senior leadership positions at Viatris (formerly Mylan), Sun Pharmaceuticals and Ranbaxy Laboratories, partnering closely with business and functional leaders across diverse geographies. Throughout his career, Abhimanyu has played a pivotal role in driving business growth, strengthening financial performance, and leading strategic transformation initiatives across global organizations. He brings broad expertise in financial strategy, business partnering, corporate governance, mergers and acquisitions, treasury, tax, risk management, and operational excellence. Abhimanyu has built strong finance teams at a global scale and partnered closely with CEOs, executive teams, boards, investors and business leaders. His leadership approach combines empowerment with accountability, helping teams contribute to decisions, take ownership and deliver results together. 5 Disclosure of relationship between Not Applicable directors (in case of appointment of a director)